UNION KOREA PHARM EGM Called to Remove All Directors and Appoint New Ones Recommended by Acquirer Buckwang Pharm Under Rehabilitation Plan

UNION KOREA PHARM has proposed at an extraordinary general meeting to remove all seven existing directors and appoint four new directors recommended by the acquirer Buckwang Pharm, in line with the approved rehabilitation plan.
The new board will include two executives from Buckwang Pharm and two independent outside directors, aiming to normalize management and improve governance.
This agenda does not involve any capital change, limiting short-term stock price impact, but investors should monitor post-acquisition strategic shifts.
[AI Summary]UNION KOREA PHARM is replacing its entire management under the rehabilitation plan with new directors nominated by acquirer Buckwang Pharm. With no capital dilution and a focus on governance improvement, the impact on shareholder value is neutral, though attention is needed on future business direction.